TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Use of Ziv Aflibercept in Different Retinal Diseases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The study included treatment naive patients suffering from recently diagnosed active myopic subfoveal or juxtafoveal CNV less than 2 months documented by fundus fluorescein angiography (FFA)and optical coherence tomography (OCT ) , pathological myopia more than 6 D was included .~Exclusion Criteria:~* Previous intraocular surgery .~* Coincident retinal pathology as diabetic retinopathy, retinal vein occlusion .~* CNV due to other causes like age related macular degeneration ,angioid streaks,trauma and choroiditis.~* Extrafoveal myopic CNV .~* Patients received other lines of treatment for CNV like photodynamic therapy ,laser photocoagulation or intravitreal injection of triamcinolone or other anti VEGF(vascular endothelial growth factor) agents.~* Known glaucoma , clinical suspicion of glaucoma or IOP(intraocular pressure) more than 20 mmHg.~* Prior ocular inflammation.~* The presence of retinal degeneration.~* Patients who didnot complete 6 months of follow up

- Gender: ALL
- Minimum Age: 31 Years
- Maximum Age: 63 Years
- Healthy Volunteers: t

Study Arms:
- ziv aflibercept patients (Type: EXPERIMENTAL): 20 eyes of myopic CNV,20 eyes with resistant diabetic macular edema and 15 eyes with non ischaemic CRVO

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Femoral Peri-arterial Local Anesthetic Injection Decreases Tourniquet Associated Ischemic Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients that will be included in the study are English speaking 18-75 year old ASA 1-3 patients undergoing total ankle arthroplasty.~Exclusion Criteria:~1. ASA 4 or 5~2. Diagnosis of chronic pain~3. Daily chronic opioid use (over 3 months of continuous opioid use).~4. Inability to communicate pain scores or need for analgesia.~5. Infection at the site of block placement~6. Age under 18 years old or greater than 75 years old~7. Pregnant women (as determined by standard of care day-of surgery urine bHCG)~8. Intolerance/allergy to local anesthetics~9. Weight \<50 kg~10. Suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years.~11. Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the investigator, may interfere with study assessments or compliance.~12. Current or historical evidence of any clinically significant disease or condition that, in the opinion of the investigator, may increase the risk of surgery or complicate the subject's postoperative course

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Mepivacaine Block Group (Type: EXPERIMENTAL): Injection of local anesthetic (mepivacaine) above and beside the femoral artery.
- Saline Sham Group (Type: PLACEBO_COMPARATOR): Injection of salt water (saline) above and beside the femoral artery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with haemophilia B (baseline level of Factor IX less than or equal to 2%)~* History of at least 150 exposure days to any Factor IX products~* Body Mass Index (BMI) below 30.0 kg/m2 (inclusive)~Exclusion Criteria:~* History of Factor IX inhibitors~* Platelet count less than 50,000 platelets/microlitre (assessed by laboratory)~* Kidney or liver dysfunction~* Scheduled surgery requiring Factor IX replacement therapy, during the trial period

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 25U/kg (Type: EXPERIMENTAL): None
- 50U/kg (Type: EXPERIMENTAL): None
- 100U/kg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Safety Study for GSK573719 in Japanese

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatient.~* A signed and dated written informed consent prior to study participation.~* Japanese subjects 40 years of age or older at Visit 1.~* Male or female subjects. A female is eligible if she is of: Non-child bearing potential or Child bearing potential agrees to one of the contraceptive methods.~* Subjects with a clinical history of COPD in accordance with the definition by COPD domestic guideline.~* Current or former cigarette smokers with a history of cigarette smoking of \>=10 pack-years at Visit 1.~* Subject with a measured post-salbutamol forced expiratory volume/forced vital capacity (FEV1/FVC) ratio of \<70% and Subjects with a measured post-salbutamol FEV1 \<80% of predicted normal values.~Exclusion Criteria (Visit 1):~* Women who are pregnant or lactating or are planning on becoming pregnant during the study.~* A current diagnosis of asthma.~* Known respiratory disorders other than COPD.~* Subjects with historical or current evidence of clinically significant abnormalities that are uncontrolled.~* A chest X-ray or computed tomography (CT) scan that reveals evidence of clinically significant abnormalities not believed to be due to the presence of COPD.~* Allergy or hypersensitivity to muscarinic, beta2-agonist, lactose/milk protein or magnesium stearate or a condition that contraindicates participation.~* Hospitalization for COPD or pneumonia within 12 weeks prior to Visit 1.~* Subjects with lung volume reduction surgery within the 12 months prior to Screening (Visit 1).~* An abnormal and significant ECG finding from the 12-lead ECG conducted at Visit 1.~* Significantly abnormal finding from clinical chemistry or hematology, tests at Visit 1.~* Use of long-term oxygen therapy (LTOT) described as oxygen therapy prescribed for greater than 12 hours a day.~* Regular use (prescribed every day, not for as-needed use) of short-acting bronchodilators (e.g., salbutamol) via nebulized therapy.~* Participation in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Visit 1.~* A known or suspected history of alcohol or drug abuse within 2 years prior to Visit 1.~* Affiliation with Investigator Site.~* Previous use of GSK573719, the GSK573719/GW642444 combination.~* Use of any other investigational medication within 30 days or 5 drug half-lives (whichever is longer).~Exclusion Criteria (Visit 2):~- COPD Exacerbation during run-in period: Subject must not have experienced a COPD exacerbation or a lower respiratory tract infection during run-in or at Visit 2.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GSK573719 (Type: EXPERIMENTAL): 125mcg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multi-center Study of Low-dose Decitabine for the Treatment of Immune Thrombocytopenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients with the diagnosis of ITP according to the International Working Group (IWG) guidelines~* failure to splenectomy or at least four standard ITP-specific treatments, but not necessarily undergone splenectomye~* baseline peripheral platelet count less than 30,000/uL or the presence of bleeding symptoms~* need of treatment(s) (including, but not limited to, low dose of corticosteroids) to minimize the risk of clinically significant bleeding. Need of on-demand or~Exclusion Criteria:~* secondary ITP~* pregnancy~* hypertension~* cardiovascular disease~* diabetes~* liver and kidney function impairment~* HCV, HIV, HBsAg seropositive status~* patients with systemic lupus erythematosus and/or antiphospholipid syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Decitabine (Type: EXPERIMENTAL): Decitabine 3.5mg/m2，ivdrip，qd x 3d, every four weeks for one cycle. It will be given three cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of AFL-assisted PDT With Short Incubation Time in Actinic Keratosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* age \>18 years~* the presence of 2-10 facial AK lesions~Exclusion Criteria:~* lactating or pregnant women~* patients with porphyria~* a known allergy to any of the constituents of the MAL cream and lidocaine~* patients with systemic disease~* history of malignant melanoma~* tendency for melasma development or keloid formation~* any AK treatment of the area in the previous 4 weeks~* any conditions associated with a risk of poor protocol compliance~* patients on immunosuppressive treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 87 Years
- Healthy Volunteers: t

Study Arms:
- 2h-AFL-PDT (Type: EXPERIMENTAL): All 440 AK lesions of the 93 patients were randomly assigned to treatment with MAL-PDT (3h-MAL-PDT) or AFL-PDT with 2 hours (2h-AFL-PDT) and 3 hours (3h-AFL-PDT) of incubation time, using restricted randomization, with a computer-generated program.
- 3hr-AFL-PDT (Type: ACTIVE_COMPARATOR): All 440 AK lesions of the 93 patients were randomly assigned to treatment with MAL-PDT (3h-MAL-PDT) or AFL-PDT with 2 hours (2h-AFL-PDT) and 3 hours (3h-AFL-PDT) of incubation time, using restricted randomization, with a computer-generated program.
- 3hr-MAL-PDT (Type: ACTIVE_COMPARATOR): All 440 AK lesions of the 93 patients were randomly assigned to treatment with MAL-PDT (3h-MAL-PDT) or AFL-PDT with 2 hours (2h-AFL-PDT) and 3 hours (3h-AFL-PDT) of incubation time, using restricted randomization, with a computer-generated program.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QAU145 in Patients With Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female (women must be post-menopausal or surgically sterile) subjects with cystic fibrosis ages 18 to 50.~Exclusion Criteria:~* Any presence of seasonal or non-seasonal allergies affecting the nose, nasal passages, throat or sinuses within 2 weeks prior to dosing.~* Any upper respiratory tract infection or signs or symptoms within 2 weeks prior to dosing.~* Any presence of nasal polyps or structural abnormalities, frequent history of nose bleeding, or any recent nasal surgery (within 12 weeks prior to dosing).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): QAU145
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects identifying their main symptom as a burning feeling in the mid epigastric area and/or chest area (ie, heartburn).~* Subject has a history of episodes of heartburn for 6 months or longer prior to Screening.~* Subject must have a history of episodes of heartburn for 4 or more days during the 7 days prior to Day -1.~Exclusion Criteria:~* Endoscopic Barrett's esophagus and/or definite dysplastic changes. History of dilatation of esophageal strictures.~* Subjects with erosive esophagitis (EE) as shown by endoscopy.~* Evidence of uncontrolled systemic disease. Co-existing diseases affecting the esophagus. Current or history of Zollinger-Ellison syndrome.~* Subject has abnormal laboratory values.~* Subjects with active gastric or duodenal ulcers within 4 weeks of the first dose.~* Subject known to have acquired immunodeficiency syndrome (AIDS).~* Known hypersensitivity to any proton pump inhibitor (PPI), any component of Dexlansoprazole MR, or antacid.~* Use of prescription or non-prescription PPIs, histamine (H2) receptor antagonists, or sucralfate.~* Chronic (\>12 doses per month) use of nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclo-oxygenase-2 (COX-2) inhibitors.~* Use of antacids (except for study-supplied Gelusil® ).~* Use of drugs with significant anticholinergic effects.~* Subjects who cannot discontinue the use of misoprostol or prokinetics~* Need for continuous anticoagulant therapy.~* Females who are pregnant or lactating.~* History of gastrointestinal surgery except for simple oversew of ulcer.~* History of cancer within 3 years prior to screening.~* Subject has participated in a previous Dexlansoprazole study.~* Subjects who, in the opinion of the investigator, are unable to comply with the requirements of the study or are unsuitable for any reason.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexlansoprazole MR 30 mg QD (Type: EXPERIMENTAL): None
- Dexlansoprazole MR 60 mg QD (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Evaluation of Maxillary Antrostomy Versus Ostial Dilation Efficacy Through Long-Term Follow-Up

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older~* maxillary sinus disease~* chronic sinusitis~Exclusion Criteria:~* fungal disease~* Samter's triad~* hemophilia~* prior sinus surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Balloon Sinus Dilation (Type: ACTIVE_COMPARATOR): XprESS Multi-Sinus Dilation Balloon, FinESS Sinus Treatment
- Functional Endoscopic Sinus Surgery (Type: ACTIVE_COMPARATOR): Traditional endoscopic sinus surgery (maxillary antrostomy and uncinectomy with optional anterior ethmoidectomy) using cutting, grasping, and microdebrider tools.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Analgesia iv vs Epidural Analgesia vs Port-sites Infiltration After Laparoscopic Sleeve Gastrectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* body mass index (BMI) \>40 Kg/m2~* BMI \> 35 Kg/m2 with the presence of comorbidities associated to obesity~Exclusion Criteria:~* patients undergoing other bariatric techniques~* severe underlying cardiovascular diseases~* chronic renal failure~* hepatic dysfunction~* previous foregut surgery~* patients with any contraindication for bariatric surgery

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Port-sites infiltration:Bupivacaine0,25% (Type: EXPERIMENTAL): Port-sites infiltration will be performed with 10 ml of Bupivacaine 0.25%, applying 2 ml under the aponeurotic layer in each port. Associated intravenous analgesia will include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours.
- Epidural analgesia:Levobupivacaine0.125% (Type: EXPERIMENTAL): Epidural analgesia consists in the placement of a thoracic epidural catheter inserted at the level T6-T7 and administration of a continuous perfusion of Levobupivacaine 0.125% 6ml/h.~Associated intravenous analgesia will include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours.
- Metamizole and Acetaminophen iv (Type: ACTIVE_COMPARATOR): Associated intravenous analgesia will include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Simvastatin on Cardiac Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* cyanotic congenital heart disease~* noncyanotic congenital heart disease with pulmonary hypertension~* Heart valve disease,~* other heart and great artery diseases need heart or great artery surgery~Exclusion Criteria:~* Coronary artery disease~* under 10-year-old.~* noncyanotic congenital heart disease without pulmonary hypertension~* poor liver function such AST elevated,Hepatitis~* Gestation women and Breast-feeding women

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- treatment (Type: EXPERIMENTAL): None
- untreated (Type: NO_INTERVENTION): control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dysport® Injection in the Treatment of Chronic Lateral Epicondylitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pain: pain will be assessed as the physician touches lateral epicondyle or passively flexing the patient's wrist and while the patient extends his/her wrist or 3rd finger against resistance. Individuals who fulfill two or more of above will be considered to have lateral epicondylitis.~* Symptom duration: should be at least 6 months.~* Previous trial of complete course of physiotherapy and corticosteroid injection.~Exclusion Criteria:~* Rheumatoid arthritis~* Generalized polyarthritis~* Local elbow arthritis~* Simultaneous medial epicondylalgia~* Bilateral lateral epicondylitis~* Neurologic deficits (abnormal light touch sensation, deep tendon reflexes abnormality, radicular pain, radial nerve entrapment, signs of nerve root compression, decreased muscle force, multiple sclerosis, seizures)~* The use of corticosteroid in last 30 days~* Simultaneous use of drugs other than acetaminophen or physical therapy in the course of study~* Pregnancy~* Breast-feeding~* Previous hand surgery~* Having a hobby or job that needs finger extension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): None
- B (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females aged ≥18 years;~2. ECOG performance status (PS) 0-2;~3. Diagnosis of systemic AL amyloidosis (subjects with non-AL amyloidosis are not eligible);~4. Received at least one prior systemic therapy, which may include stem cell transplant, for AL amyloidosis;~5. Have adequate organ function;~6. Ability to understand and willingness to sign informed consent prior to initiation of any study procedures.~Exclusion Criteria:~1. Secondary or familial amyloidosis;~2. Life expectancy of \< 3 months;~3. Symptomatic multiple myeloma;~4. Hypersensitivities to other monoclonal antibodies;~5. Known HIV infection;~6. Women who are lactating;~7. Any other condition or prior therapy, which in the opinion of the PI, would make the subject unsuitable for the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NEOD001 (Type: EXPERIMENTAL): NEOD001 will be administered intravenously once every 28 days. The starting dose will be 0.5 mg/kg. Dose escalation will continue until the the maximum tolerated dose is determined for single agent NEOD001. Approximately 20 additional subjects will be treated with the maximum tolerated dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete